Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine-dependent effect

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1982-1990

  Huang, Liqun ^a   Zhu, Caihua ^a   Sun, Yu ^a   Xie, Gang ^a   Mackenzie, Gerardo G ^a   Qiao, George ^a   Komninou, Despina ^b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOOXYGENASE 1; EFLORNITHINE; OXT 922; PHOSPHOSULINDAC; POLYAMINE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; SPERMIDINE; SPERMINE; SULINDAC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOKINESIS; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; PANCREAS CANCER; PRIORITY JOURNAL;

ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASES; CYCLOOXYGENASE 1; DINOPROSTONE; EFLORNITHINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATION-REDUCTION; POLYAMINES; REACTIVE OXYGEN SPECIES; SULINDAC;

EID: 78149248334     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq149     Document Type: Article

References (45)

1. Husain, S.S. et al. (2002) NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol., 97, 542-553.
2. Shiff, S.J. et al. (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J. Exp. Med., 190, 445-450.
3. Hanif, R. et al. (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol., 52, 237-245.
4. Gao, J. et al. (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl Acad. Sci. USA, 102, 17207-17212.
5. Babbar, N. et al. (2003) Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J. Biol. Chem., 278, 47762-47775.
6. Mahmud, S.M. et al. (2010) Use of non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: a meta-analysis. Int. J. Cancer.
7. Baron, J.A. (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res., 37, 1-24.
8. Giardiello, F.M. et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346, 1054-1059.
9. Viswanathan, A.N. et al. (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res., 68, 2507-2513.
10. Knights, K.M. et al. (2005) Novel mechanisms of nonsteroidal antiinflammatory drug-induced renal toxicity. Expert Opin. Drug Metab. Toxicol., 1, 399-408.
11. Lazzaroni, M. et al. (2009) Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs, 69, 51-69.
12. Rigas, B. (2007) The use of nitric oxide-donating nonsteroidal antiinflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol., 23, 55-59.
13. Piazza, G.A. et al. (2009) A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev. Res. (Phila Pa), 2, 572-580.
14. Shiff, S.J. et al. (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96, 491-503.
15. Malumbres, M. et al. (2005) Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 30, 630-641.
16. Rigas, B. et al. (2008) Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br. J. Cancer, 98, 1157-1160.
17. Sun, Y. et al. (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res., 68, 8269-8277.
18. Alexandre, J. et al. (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res., 67, 3512-3517.
19. Woo, S.H. et al. (2004) Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int. J. Cancer, 112, 596-606.
20. Bass, D.A. et al. (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol., 130, 1910-1917.
21. LeBel, C.P. et al. (1992) Evaluation of the probe 2′, 7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol., 5, 227-231.
22. Trachootham, D. et al. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 8, 579-591.
23. Zamzami, N. et al. (1995) Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med., 181, 1661-1672.
24. Vayssiere, J.L. et al. (1994) Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc. Natl Acad. Sci. USA, 91, 11752-11756.
25. Smiley, S.T. et al. (1991) Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl Acad. Sci. USA, 88, 3671-3675.
26. Riedl, S.J. et al. (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol., 5, 897-907.
27. Hennessy, B.T. et al. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 4, 988-1004.
28. Fruehauf, J.P. et al. (2007) Reactive oxygen species: a breath of life or death? Clin. Cancer Res., 13, 789-794.
29. Bubici, C. et al. (2006) The NF-kappaB-mediated control of ROS and JNK signaling. Histol. Histopathol., 21, 69-80.
30. Perez, M.J. et al. (2001) Spin trapping agents (Tempol and POBN) protect HepG2 cells overexpressing CYP2E1 against arachidonic acid toxicity. Free Radic. Biol. Med., 30, 734-746.
31. Giulivi, C. et al. (1993) Inhibition of protein radical reactions of ferrylmyoglobin by the water-soluble analog of vitamin E, Trolox C. Arch. Biochem. Biophys., 303, 152-158.
32. Zhao, W. et al. (2009) Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis, 30, 512-519.
33. Williams, J.L. et al. (2008) NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis, 29, 390-397.
34. Williams, J.L. et al. (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res., 63, 7613-7618.
35. Saitoh, M. et al. (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J., 17, 2596-2606.
36. Woodcock-Mitchell, J. et al. (1982) Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J. Cell Biol., 95, 580-588.
37. Gerner, E.W. et al. (2004) Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer, 4, 781-792.
38. Meyskens, F.L. Jr. et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila Pa), 1, 32-38.
39. Minami, T. et al. (2005) Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin. Cancer Res., 11, 5248-5256.
40. Seo, S.K. et al. (2008) Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol. Pharmacol., 73, 1005-1012.
41. Marchetti, M. et al. (2009) Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One, 4, e5804.
42. D'Autreaux, B. et al. (2007) ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol., 8, 813-824.
43. Hundley, T.R. et al. (2006) Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther., 316, 25-34.
44. Hatfield, D.L. et al. (2009) Selenoproteins that function in cancer prevention and promotion. Biochim. Biophys. Acta., 1790, 1541-1545.
45. Mukherjee, A. et al. (2008) The thioredoxin system: a key target in tumour and endothelial cells. Br. J. Radiol., 81 Spec No 1, S57-S68.